Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Bookmark and Share
Published: 1 Jun 2019
Views: 333
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain

Dr Josep Tabernero presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from the KEYNOTE-062 trial.

The trial reached its primary endpoint, showing that overall survival for pembrolizumab was non-inferior (comparable) to standard chemotherapy.

​Watch the interview here.

Watch Dr. Schilsky's comment here.